These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29748173)

  • 1. Do direct acting antivirals cure chronic hepatitis C?
    Jakobsen JC; Nielsen EE; Koretz RL; Gluud C
    BMJ; 2018 May; 361():k1382. PubMed ID: 29748173
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C.
    Mondelli MU
    Gastroenterology; 2015 Jul; 149(1):25-8. PubMed ID: 26021236
    [No Abstract]   [Full Text] [Related]  

  • 3. Modulation of the Natural Killer Cell Compartment during DAAs treatment in Interferon-naïve HCV patients: The type of DAA matters.
    Nicolini LA; Dettori S; Bozzano F; Di Biagio A; De Maria A
    Immunol Lett; 2018 Nov; 203():112-115. PubMed ID: 30144471
    [No Abstract]   [Full Text] [Related]  

  • 4. Natural killer cells in hepatitis C: Current progress.
    Yoon JC; Yang CM; Song Y; Lee JM
    World J Gastroenterol; 2016 Jan; 22(4):1449-60. PubMed ID: 26819513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of Direct-Acting Antivirals for Hepatitis C.
    Lok AS; Chung RT; Vargas HE; Kim AY; Naggie S; Powderly WG
    Ann Intern Med; 2017 Dec; 167(11):812-813. PubMed ID: 29049502
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of hepatitis C infection before and after liver transplantation.
    Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
    World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses in hepatitis C virus infection and mechanisms of hepatitis C virus persistence.
    Hiroishi K; Ito T; Imawari M
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1473-82. PubMed ID: 18761560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro: Direct-acting antivirals are associated with occurrence and recurrence of hepatocellular carcinoma.
    Trotter JF
    Liver Transpl; 2017 Dec; 23(12):1593-1595. PubMed ID: 29024516
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C.
    Younossi Z; Henry L
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S186-96. PubMed ID: 25458773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era.
    Teriaky A; Reau N
    Clin Liver Dis; 2015 Nov; 19(4):591-604, v. PubMed ID: 26466649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
    Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
    Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.
    Bickerstaff C
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):787-800. PubMed ID: 26289734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment.
    Dessouki O; Kamiya Y; Nagahama H; Tanaka M; Suzu S; Sasaki Y; Okada S
    Biochem Biophys Res Commun; 2010 Mar; 393(2):331-7. PubMed ID: 20138830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.
    Ahmed A; Felmlee DJ
    Viruses; 2015 Dec; 7(12):6716-29. PubMed ID: 26694454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.
    Fernández-Yunquera A; Rincón D; Salcedo M; Bañares R
    Rev Esp Quimioter; 2013 Sep; 26(3):189-92. PubMed ID: 24080883
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
    Lo AO; Chan HL; Wong VW; Wong GL
    J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.
    Spaan M; van Oord G; Kreefft K; Hou J; Hansen BE; Janssen HL; de Knegt RJ; Boonstra A
    J Infect Dis; 2016 Jan; 213(2):216-23. PubMed ID: 26223768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.